FDA Approves First Glucose Monitoring System for Weight Management in US

Weight loss injections like Mounjaro and Wegovy have helped many shed pounds but are not universally effective, with some users reporting minimal results or side effects such as nausea and bloating. Experts emphasize that these GLP-1 medications require complementary lifestyle changes, including diet and exercise, to work effectively. New innovations aim to improve weight management outcomes, including the Gastric Alimetry pad, a device that monitors stomach activity to tailor jab dosages and reduce side effects, and Signos’ FDA-approved continuous glucose monitor app that provides personalized insights to support weight loss without drugs or surgery. Additionally, researchers are developing natural alternatives, such as edible microbeads made from green tea polyphenols and seaweed, which target fat absorption in the gut and may offer safer, noninvasive options. Support groups like Slimming World highlight the importance of emotional and lifestyle support to maintain weight loss after stopping injections, addressing the risk of weight regain. These developments reflect a growing, multifaceted approach to obesity management that combines medical, technological, and behavioral strategies.